Quantcast

Latest Metastatic urothelial carcinoma Stories

2012-04-02 09:14:34

The antiangiogenic drug pazopanib has demonstrated clinically meaningful activity in patients with refractory urothelial cancer, according to results presented at the AACR Annual Meeting 2012, held here March 31 - April 4. The results also revealed that increases in interleukin-8 levels early after treatment with pazopanib may predict a lack of tumor response to the therapy. "Historically, prognosis of patients with relapsed or refractory urothelial cancer is quite dismal," said Andrea...

2011-05-12 07:30:28

(Ivanhoe Newswire) -- A new study shows a combination treatment might be better than the drug gemcitabine at improving survival among patients with pancreatic cancer that has spread to other areas of the body. Pancreatic cancer often has a poor prognosis even when it is diagnosed early. The cancer typically spreads rapidly and is seldom detected in early stages. According to the National Cancer Institute, about 43,140 new cases of pancreatic cancer were diagnosed in 2010. About 36,800 people...

2010-06-06 07:51:49

The combination of two different chemotherapies and a previously approved treatment for kidney and liver cancers is not effective against advanced melanoma, according to results disclosed in an oral presentation June 5th at the 46th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. "With each new study, we learn something important about the treatment of melanoma," said John M. Kirkwood, M.D., professor of medicine, University of Pittsburgh School of Medicine, and...

2009-05-26 22:46:00

Novel chemotherapy and biological agents for metastatic colorectal cancer has resulted in increased patient survival, U.S. researchers say. Researchers at the University of Texas M.D. Anderson Cancer Center in Houston said researchers have made great strides in identifying active agents for the disease, resulting in U.S. Food and Drug Administration approval of numerous chemotherapeutic agents. The study, published in the Journal of Clinical Oncology, found that the median overall survival...

2006-02-01 07:53:44

TORONTO (Reuters) - Lorus Therapeutics Inc. said on Wednesday data from Phase 3 trials of its Virulizin(R) cancer treatment showed a significant survival benefit for a subgroup of patients. The Canadian company said the finding from its exploratory analysis would not be sufficient for regulatory approval without additional clinical investigation. Lorus said patients who remained on Virulizin(R) demonstrated a median survival of 10.9 months, compared with 7.4 months for patients on a...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'